Objective: Aortic dissection is a dynamic process that can progress both proximal and distal to the initial entry tear. We sought to determine associations for development of proximal progression or new type A aortic dissection (NTAD) after acute type B dissection (ATBD) and its effect on survival of the patient.
The incidence of acute thoracic aortic dissection is estimated to be 6 new cases per year per 100,000 population. 1 In patients with hypertension, the incidence increases to >20 per 100,000. 2 Dissection involving the ascending aorta (Stanford A or DeBakey I/II) is the most deadly, with the highest mortality occurring in the first month. 3 Dissection limited to the descending thoracic aorta (Stanford B or DeBakey III) has more favorable early mortality 4 and can be treated with medical management, open surgery, or, more recently, thoracic endovascular aortic repair (TEVAR).
The phenomenon of new proximal or retrograde dissection progression into the ascending aorta is commonly associated with TEVAR in the descending thoracic aorta. [5] [6] [7] [8] [9] [10] [11] [12] Most authors include only TEVAR patients in their reporting of new type A aortic dissection (NTAD). Less is known about the incidence of NTAD in medically or surgically managed acute type B aortic dissection (ATBD) patients without TEVAR. Also, because intramural hematoma (IMH) is associated with fewer instances of malperfusion syndrome, 13 we further tested the association with NTAD occurrence. The main purpose of this study was to define the incidence, to identify risk factors, and to analyze the effect of NTAD on longterm survival after ATBD.
METHODS
All aortic disease patients managed by our group at a tertiary referral practice since 1999 are enrolled in a departmental registry approved by the Committee for the Protection of Human Subjects, the local Institutional Review Board. New patients are prospectively enrolled after a written consent form is obtained allowing us to periodically monitor their quality of life, clinical outcomes, and relevant follow-up data for research and quality assurance. Retrospective access to this database was granted with a waiver of consent. Pediatric The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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Patients with aortic dissection from 1999 to 2014 were categorized by location of entry tear using the DeBakey and Stanford classifications. Patients with known ATBD were queried for development of NTAD. Patients who developed NTAD during the study period were counted in group A; those with no new dissection were counted in group B. Patients who developed new or retrograde dissection in the aortic arch but not involving the ascending aorta were included in group B.
Patients were also classified on the basis of the radiologic type of dissection.
14 Classic dissection was defined as having flap with or without a visible entry tear. IMH was defined as disruption of the medial layer of the aortic wall without radiologic or intraoperative evidence of intimal tear or disruption. An adjunctive diagnosis of penetrating aortic ulcer (PAU) was given in the setting of aortic atheromatous disease that appeared to disrupt the intima into the medial layer. Cases of PAU without classic dissection or IMH were not included in the study. 18 Some high-risk patients, such as with massive stroke causing coma, metastatic cancer, advanced dementia, and other severe comorbid disease, were offered palliative care. By itself, the presence of stroke without coma was not considered to be a prohibitive surgical risk. 19 Some coma patients were offered repair after neurologic improvement.
Statistical analysis. Analysis was performed in two sets: one for ascertaining the predictors or factors that defined the risk for NTAD, and another for analysis of independent and joint effects of these baseline clinical correlates on overall risk for mortality. Univariate risk factors for NTAD and in-hospital as well as long-term outcomes were computed using contingency table methods for discrete variables and t-tests or Wilcoxon rank sum statistics for continuous variables. Continuous variables were compared between groups with unpaired t-test and are presented as mean 6 standard deviation for normally distributed data. The Mann-Whitney U test was used to assess the difference between two independent groups when normal distributional assumptions were not met and are presented as median and interquartile range (IQR). P values were estimated using log-rank tests to evaluate statistical significance of differences in longterm survival. A P value of # .05 was considered significant. Multivariable analyses for in-hospital outcomes and for NTAD overall were conducted using multiple logistic regression (MLR) and long term by multiple Cox proportional hazards regression. In addition, multivariable attributable risk estimates were computed using generalized linear models to analyze the adjusted percentage risk of these predictors of NTAD attributable to the individual factor. After an initial screening of univariate risk factors (depicted in Tables I and II) , we performed a Spearman correlation analysis to identify determinants of NTAD after ATBD. We then conducted multivariable analysis on all of these factors through multiple Cox regression to account for censoring in a failure-time distribution framework, with stepwise model selection followed by purposeful selection. We then performed MLR with the same variable set to determine whether censoring influenced the results enough to preclude use of a prevalence-based dependent variable mode that could be used to compute probability. Model diagnostics were performed by influence and residual analysis, area under curve, and Akaike information criteria. A risk score for NTAD was constructed using MLR, and the equation was solved for each patient and the probability estimate used as a covariate in further multivariable analyses of survival. All diagnostics indicated appropriate model fit.
Survival data were obtained from office records and augmented with the Social Security Death Master File. Long-term survival, stratified by NTAD, was assessed using Kaplan-Meier analysis and stratified multiple ARTICLE HIGHLIGHTS proportional hazards regression. Furthermore, Cox proportional hazards analysis was performed to analyze the risk-adjusted effects of NTAD on overall mortality after accounting for correlates of proximal dissection progression. All computations were performed using SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
During the study period from 1999 to 2014, we treated 1049 acute aortic dissection patients. There were 477 ATBD patients who were admitted with a mean age of 60.2 6 14.1 (range, 16-98) years. Most patients were male (63.3%) and classified as uncomplicated (59.1%). During a median follow-up of 4.1 (IQR, 1.4-7.7) years, 19 patients developed NTAD (4.0%, group A overall; 7% actuarial cumulative incidence at 10 years). Twenty-two percent were lost to follow-up. Two of the 19 patients were asymptomatic, and the NTAD was discovered on surveillance imaging. Thus, 458 ATBD patients were not known to have NTAD during follow-up (96.0%, group B). Two patients had dissection progression into the aortic arch but the ascending aorta was spared; these were counted in group B. The median time from ATBD diagnosis to NTAD was 124 (IQR, 23-1201) days. The risk of NTAD was greatest soon after initial ATBD diagnosis, with an actuarial incidence of 2.5% 6 0.7% in the first 6 months (Fig 1) . There were no differences in most comorbid conditions between group A and group B (Table I) . Specifically, there were no increased associations with substance abuse, Marfan disease, and other connective tissue disorders. Bicuspid aortic valve appeared to be statistically associated with NTAD based on a small number of patients (Table I) . Group A patients were younger (mean age, 51.0 6 14.2 vs 60.6 6 14.0 years; P ¼ .003) and were less likely to complain of back pain on admission (P ¼ .054). Group A patients were also more likely to have better baseline renal function (P ¼ .097). There was a trend toward a higher frequency of pericardial effusion on admission in group A patients, but this did not reach statistical significance (26.3% vs 12.0%; P ¼ .065).
Most ATBD patients were medically managed (75.9%). In patients requiring thoracic aortic repair, 46 (9.6%) were treated with open surgery and 43 (9.0%) had TEVAR (Table II) . One patient had infrarenal endovascular aneurysm repair among 25 (5.2%) patients who had nonthoracic aortic and peripheral revascularization procedures. There was no significant difference in NTAD occurrence between patients requiring intervention on the descending thoracic aorta and those who did not (5.6% vs 3.6%; P ¼ .328). Specifically, there was no association with TEVAR (P ¼ .240) or open surgical repair (P ¼ .704) of the descending thoracic aorta and NTAD.
Despite a lower association with peripheral malperfusion (5% with IMH vs 15% without), 13 IMH with or without PAU did not significantly affect the rate of NTAD (P ¼ .808). Two patients in the NTAD group had aortic rupture. One was admitted with contained rupture of the descending thoracic aorta and was treated with open surgery. The other was initially medically managed but had persistent hypertension and a lengthy hospitalization due to complications and ultimately developed NTAD with rupture into the ascending aorta. This patient died in the operating room during attempted NTAD repair. On multivariable regression modeling for correlates of NTAD, the baseline predictors of aggregate risk (Table III by MLR and generalized linear model methods) and incident risk (Table IV by Cox proportional hazards analysis) with the largest independent effects include bicuspid aortic valve, age <60 years, and pericardial effusion during initial hospitalization. Although TEVAR was not statistically significant in a prevalence-based analysis, it did appear to have some effect during stepwise regression modeling for long-term risk of NTAD. Overall 30-day mortality was 6.9%, with no difference between group A and group B (P ¼ 1.000). The 5-year survival for the entire cohort was 70.2%. However, the long-term survival between the groups was at the margin of statistical significance on unadjusted analysis. Survival at 1, 5, and 10 years in group A vs group B was 94.7%, 94.7%, and 77.2% vs 84.8%, 69.1%, and 60.1% (log-rank, P ¼ .051).
Assessment of risk-adjusted long-term mortality by multiple Cox regression analysis demonstrated that age $65 years, Marfan syndrome, low baseline renal function, need for open or endovascular aortic intervention on the descending thoracic aorta, and medically managed complicated dissections were independently associated with increased mortality in long-term follow-up (Table V) . After adjusting for factors correlated with increased probability of NTAD, the survival benefit with repair of the ascending aorta was suggestive but no longer statistically significant (Fig 2; P ¼ .089 ). Further examination of the effect of correlates of NTAD and any potential confounding, effect modification, or interaction with risk factors for mortality by Cox proportional hazards regression demonstrated that neither NTAD nor the risk associated with it was independently associated with mortality, P ¼ .117 and .074, respectively (Table V) .
DISCUSSION
During the study period, the incidence of NTAD in the ascending aorta after ATBD occurred in 3.6% of medically managed uncomplicated patients, 4 .3% of open aortic surgery cases, and 6.9% of TEVAR patients. The overall incidence was 4.0% during a mean follow-up of 58 months. This is similar to other reports in the literature, taking into account our follow-up length and that we report only patients with pre-existing dissection disease.
Hata et al 20 reported on 180 type B dissection patients during a mean follow-up of 51 months. Patients were primarily managed medically except for complicated disease, and they discovered four (2.2%) cases of NTAD. Onitsuka et al 21 reported one case out of 76 patients (1.3%) during a mean follow-up of 52 months. Winnerkvist et al 22 reported on 66 medically managed ATBD patients during a mean follow-up of 79 months. They found five (7.6%) cases of NTAD with 80% subsequent mortality. There was a weak effect, if any, of TEVAR on NTAD in our study (7% vs 4%; P ¼ .240). NTAD is frequently described in the literature as a consequence of TEVAR in series that do not report the experience of medically or surgically managed controls. The prevalence of these uncontrolled series may lead to the impression that NTAD mostly or only follows TEVAR. Our findings show that the focus should be on the risk differencedthe excess risk above background NTAD ratedto examine the attributable risk of TEVAR, which is by design not addressed in the published uncontrolled series without medically managed patients. We found a 4% background risk of NTAD among medically managed ATBD patients. Hence, only 3% excess risk can really be attributed to TEVAR rather than the total risk of 7% as reported in uncontrolled series.
Canaud et al 23 reported an incidence of NTAD of 1.6%
after TEVAR from the Medtronic Outcomes of Thoracic Endovascular Repair (MOTHER) registry. However, the MOTHER registry is a combination of several industrysponsored studies involving both aneurysm and dissection diseases. Aneurysm disease is less associated with new or retrograde dissection, and the follow-up reported in many of these studies is 12 months or less. 12, [24] [25] [26] [27] In a systematic review of TEVAR with distal bare stents in acute and chronic type B dissection, the overall occurrence of NTAD was 3.7%. 28 This occurrence is similar to our current study, despite the shorter follow-up. Although the majority of the NTADs occur within the first 6 months, the risk persists beyond this, and cases will be missed with short follow-up. Probability of NTAD was calculated from multiple logistic regression (MLR) analysis in Table III and was not an independent risk for mortality.
We found that ascending aortic repair had no significant deleterious effect on long-term mortality after NTAD after ATBD. Even after NTAD risk score adjustment and accounting for perioperative mortality, we were surprised to find that survival after NTAD in our ATBD patients was no worse than in the rest of the cohort. Although it may be counterintuitive that NTAD had equal or better survival, it is more accurate to state that only patients who survive to proper diagnosis and treatment of NTAD claim this benefit. Many NTAD patients die in the prehospital setting or from misdiagnosis. We surmise that some of our group B ATBD cases died of complications of NTAD despite never being diagnosed. It is plausible that some mortality ascribed to false aneurysm rupture of the dissected descending thoracic aorta may be due to NTAD.
Although bicuspid aortic valve was associated with risk of NTAD (Tables III and IV) , the analysis was based on such a small number of patients that we find it difficult to interpret its clinical significance. However, coupled with the independent risk of youth (age <60 years), this does suggest an underlying genetic component and requires further study. Also unclear is the pathophysiologic mechanism of pericardial effusion at initial diagnosis of ATBD and its predictive role in future NTAD (Table IV) . One of the limitations of our study is that some of our patients were lost to follow-up and could have had aortic interventions at other institutions. We previously reported that adequate follow-up in our ATBD cohort was 78%, 15 and we augmented database records with mortality from the Social Security Death Master File.
Other limitations include the assignment of IMH on the basis of single-or dual-phase contrast-enhanced computed tomography and the evolving definition and treatment of complicated ATBD. Our experience may not be comparable to that of other centers because of differing expertise in aortic surgery and management of acute aortic dissections.
We were also limited by our sample size and event rate for the outcomes of interest. Based on our current sample size, the power analysis demonstrated that our study was sufficiently powered ($80%) to detect an effect size of moderate to large difference (odds ratio [OR], #0.29 or $3.5). However, there was <50% chance of detecting significance for smaller effect sizes (OR, 0.4-2.5). Based on this, significant baseline factors for NTAD include bicuspid aortic valve (OR, 26.2; P ¼ .009) and age <60 years (OR, 4.5; P ¼ .012). TEVAR did not have a significantly large effect, although it may have an undetected small or moderate effect on risk. To detect a moderate effect size (OR, <3.5) with a relatively low event rate (4%) with 80% power, a sample size of >2100 would be required.
CONCLUSIONS
We found a 4% background risk of NTAD among medically managed ATBD patients, and this risk was highest in the first 6 months after diagnosis. The excess risk attributed to TEVAR was 3%, but this was not statistically significant. Timely diagnosis and repair of NTAD are associated with good survival rates. Lifelong surveillance is warranted in all cases of descending thoracic aortic dissection, regardless of initial treatment modality. 
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